Issue 94

COMPASS Pathways' new CEO Kabir Nath

In July, COMPASS Pathways’ share price rose 40% – far outpacing the market’s rebound.

Notable inflection points included the release of positive financial results, conclusion of the patent dispute, the US government’s expectation that COMP360 will be regulated within the next 24 months, and the appointment of a CEO with extensive expertise in drug commercialisation.

Kabir Nath was previously Senior Managing Director of Global Pharmaceuticals at Otsuka, and served as President and CEO of Otsuka’s North America Pharmaceutical Business. To discuss the company’s transition and his mandate going forward, Nath sat down with PSYCH.

A$250M VC FUND TO FINANCE PSYCHEDELIC HEALTHCARE

Tattarang Ventures launches Tenmile to support the development of MDMA-assisted therapy.

UK-BASED AWAKN LIFE SCIENCES EXPANDS INTO US

Stocks in the company surged 17%, as it targets addiction across the Atlantic.

BUSINESS AND INVESTMENT

atai, Awakn, Filament Health and MindMed release financial results.

Ketamine for alcohol-use disorder.

MHRA approves Small Pharma’s DMT and SSRI study.

A need for investment in therapy, not drugs.

Field Trip Health Ltd. renamed Reunion Neuroscience Inc.

Shortwave enters clinical trial agreement with the Sheba Research Fund.

Optimi Health approved to produce MDMA.

SCIENCE AND RESEARCH

LSD’s impact on the connectivity of anticorrelated networks.

Petition – reschedule psilocybin in the UK.

Psychedelic medicines for memory loss.

The Psychedelics as Medicine Report provides market insights from industry experts.

With over 60,000 downloads, the flagship publication contains proprietary data for regulators, researchers and investors to make informed decisions.

Previous partners include atai Life Sciences, COMPASS Pathways, Cybin and Filament Health.

To be included in the fourth edition and to discuss future events, please contact grace@psych.global

CONTACT FORM

REGULATION AND LEGISLATION

California bill amended to remove therapy component.

Psilocybin legalisation in Canada.

ARTICLES OF INTEREST

UK economy shrinks 0.1% in Q2 2022.

Why mental health is a public health issue.

NHS fails on mental health care targets.

Decline in mental health of children in Canada.

Youth emergency mental health referrals at record high.